Program
RET Inhibitor HS-10365
Also written as “HS-10365” and “HS-10365 capsules”.
In Hansoh Pharmaceutical Group’s pipeline, RET
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Hansoh Pharmaceutical Group.
Furthest: phase 2, since Jan 9, 20223 company-led studies, 3 open or runningNext primary completion: Aug 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 33 open or running | phase 2since Jan 9, 2022 | Jan 9, 2022 | Aug 31, 2027phase 2 · NCT06147570 |
- Named in Hansoh Pharmaceutical Group’s own pipeline as
HS-10365 (RET)
, phase 4, as of Aug 26, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 9, 2022First study: phase 2 study in Solid TumorFirst studyNCT05207787 · 306 planned · China
- Nov 17, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06147570 · 62 planned · China
- Dec 23, 2024Phase 1 study in Carcinoma, Non-Small-Cell LungNCT06823258 · 32 planned
Ahead
- Aug 31, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06147570
TargetBeta
“RET”the company's pipeline, read by Claude · source
“An orally bioavailable selective inhibitor of the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), ”NCIt, by rule
Other programs on RET
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| regorafenibrule | Bayer | phase 4 | 40 |
| selpercatinibrule | Eli Lilly | phase 4 | 19 |
| pralsetinibrule | Hoffmann-La Roche | phase 4 | 7 |
| quizartinibrule | Daiichi Sankyo | phase 3 | 22 |
| TRK/RET Inhibitor ND-003rule | shenzhen-newdel-biotech-co-ltd | phase 2 | 3 |
| RET Inhibitor FHND5071 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06823258Carcinoma, Non-Small-Cell Lung | 1 | Not yet recruiting | Jul 31, 2025 | 32 |
| NCT06147570Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Aug 31, 2027 | 62 |
| NCT05207787Solid Tumor · China | 2 | Recruiting | Apr 30, 2024 | 306 |
How it is read
Names in the registry
- “HS-10365”, 2 entries
- “HS-10365 capsules”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.